| Market Cap | 148.45M | P/E | - | EPS this Y | 81.70% | Ern Qtrly Grth | - |
| Income | -124.65M | Forward P/E | -3.19 | EPS next Y | - | 50D Avg Chg | -7.00% |
| Sales | - | PEG | -0.31 | EPS past 5Y | - | 200D Avg Chg | -8.00% |
| Dividend | N/A | Price/Book | 0.54 | EPS next 5Y | 25.90% | 52W High Chg | -43.00% |
| Recommedations | 3.00 | Quick Ratio | 38.41 | Shares Outstanding | 58.24M | 52W Low Chg | 61.00% |
| Insider Own | - | ROA | -17.99% | Shares Float | 2.38M | Beta | 0.20 |
| Inst Own | - | ROE | -51.95% | Shares Shorted/Prior | 100.58K/114.54K | Price | 2.56 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 144,730 | Target Price | 7.00 |
| Oper. Margin | - | Earnings Date | - | Volume | 141,599 | Change | 1.79% |
As of March 21, 2024, Graphite Bio, Inc. was acquired by LENZ Therapeutics, Inc., in a reverse merger transaction. Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 10% Owner 10% Owner | Apr 11 | Buy | 4.08 | 424,464 | 1,731,813 | 8,459,314 | 04/13/22 |
| Gutry Phil | CHIEF BUSINESS OFFIC.. CHIEF BUSINESS OFFICER | Apr 11 | Buy | 4.01 | 5,000 | 20,050 | 299,941 | 04/13/22 |
| Samsara BioCapital, L.P. | 10% Owner 10% Owner | Jan 21 | Buy | 8.85 | 123,000 | 1,088,550 | 8,034,850 | 01/25/22 |
| Samsara BioCapital, L.P. | 10% Owner 10% Owner | Oct 13 | Buy | 12.74 | 50,800 | 647,192 | 7,590,166 | 10/15/21 |
| Samsara BioCapital, L.P. | 10% Owner 10% Owner | Oct 06 | Buy | 13.96 | 145,496 | 2,031,124 | 7,539,366 | 10/08/21 |